Trends in funding for coronavirus vaccine research and development: implications for preparedness against future coronavirus threats
npj Vaccines·
- DOI
- 10.1038/s41541-026-01493-x
- PMID
- 42191709
- PMCID
- —
- OpenAlex
- W7162454749
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings suggest that reduced sustained investment in coronavirus vaccine research may weaken global preparedness and response capacity against future emergent coronavirus threats.
Structured evidence summary
Research question
The study examined trends in grant funding for coronavirus vaccine research and development from 2020 through 2025, focusing on the trajectory of investment following the initial COVID-19 pandemic response.
Study design
The authors mapped coronavirus vaccine grant support over a six-year period (2020–2025), analyzing publicly available funding patterns and shifts in research focus.
Population and setting
The analysis focused on grant funding data with particular attention to the United States, though the study addressed global preparedness implications.
Main findings
Funding showed an early surge concentrated on ancestral SARS-CoV-2 vaccines, followed by a pivot toward broadly protective coronavirus vaccines. Subsequently, overall publicly available funding declined steeply, with the decline particularly pronounced in the United States.
Public-health relevance
The findings suggest that reduced sustained investment in coronavirus vaccine research may weaken global preparedness and response capacity against future emergent coronavirus threats.
Important limitations
This summary is limited to the supplied single-article abstract and metadata. The original paper is required for decision-grade interpretation of methodology, data sources, funding classification criteria, and completeness of the funding landscape captured.
GIDS interpretation
This article was identified through disease and topic classifiers linking it to COVID-19, SARS, vaccination, and United States contexts. It provides policy-relevant context on research funding trends but does not report primary surveillance data on disease incidence or vaccine effectiveness.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.